Narrative review offers qualitative synthesis without reported quantitative outcomes or safety data.

Cancer immunotherapy has remarkably reshaped the therapeutic landscape of oncology, and representative therapies including immune checkpoint inhibitors, adoptive cell therapy, oncolytic viruses and tumor vaccines have exhibited superior efficacy over conventional treatments in a broad spectrum of malignancies. Nonetheless, its clinical translation and application are still hampered by four core challenges: insufficient exploration of novel immune targets, inherent limitations of immunotherapeutic monotherapies, the lack of effective strategies for remodeling the microenvironment of cold tumors, and the immaturity of precise patient stratification systems. To address these aforementioned challenges, this review systematically outlines four core future development directions of cancer immunotherapy. First, the multi-dimensional excavation of novel therapeutic targets based on differential cellular expression molecules, metabolic regulatory networks, the tumor microenvironment and immune cell interactions. Second, the innovative upgrading of core therapeutic technologies encompassing engineered bacteria, oncolytic viruses, adoptive cell therapy and tumor vaccines. Third, the remodeling of the immunosuppressive microenvironment of cold tumors through the optimization of combination therapeutic strategies. Fourth, the construction of an integrated artificial intelligence-multi-omics model for precise patient stratification, so as to achieve dynamic prediction of therapeutic efficacy and accurate screening of populations that can derive the maximal benefit from immunotherapies. In the future, it will be necessary to deeply decode the dynamic interaction networks among tumors, the immune system, and the host. By integrating AI and multi-omics technologies, we should propel the evolution of cancer immunotherapy toward a closed-loop system featuring diagnosis, intervention and real-time monitoring, ultimately maximizing the clinical benefits of individualized treatment for cancer patients.